Modulation of Rb phosphorylation and antiproliferative response to palbociclib. The Preoperative-Palbociclib (POP) randomized Clinical Trial.
Conclusion: Short-term pre-operative palbociclib decreases Ki67 in early breast cancer patients. Early decrease of Rb phosphorylation correlates with drug's effect on cell proliferation and could potentially identify patients with primary resistance.
PMID: 29893769 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Arnedos M, Bayar MA, Cheaib B, Scott V, Bouakka I, Valent A, Adam J, Leroux-Kozal V, Marty V, Rapinat A, Mazouni C, Sarfati B, Bieche I, Balleyguier C, Gentien D, Delaloge S, Lacroix-Triki M, Michiels S, Andre F Tags: Ann Oncol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Fish | Genetics | HER2 | Hormones | Oral Cancer